Laboratori d'Enginyeria Genètica Animal i Teràpia Gènica

  • Postal addressShow on map

    Edifici H. Campus de la UAB

    08193 Bellaterra (Cerdanyola del Vallès)


Organisation profile

Organisation profile

Our research focuses on developing gene therapy approaches for highly prevalent diseases, such
as diabetes mellitus and obesity, and rare metabolic/neurodegenerative diseases. Obesity and
type 2 diabetes, strongly associated with deficits in cognitive function, are a major health
problem because of their alarming growing prevalence worldwide. Novel adeno-associated viral
(AAV) vector-mediated gene therapy strategies are used to target these pathophysiological
processes. We are also developing gene therapies for Mucopolysaccharidosis, a group of
devastating lysosomal storage diseases that currently lack effective treatments. We aim at
developing gene therapies that are minimally invasive, safe and could guarantee maximal
efficacy in the most affected organs. The know-how derived from these studies is also used to
assess the effectiveness of AAV-based gene therapeutics products to counteract other
neurodegenerative diseases and rare diseases affecting the skeletal system in mouse models

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. Our work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being


Dive into the research topics where Laboratori d'Enginyeria Genètica Animal i Teràpia Gènica is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or